Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels
John Mascarenhas(Tisch Hospital), Jean‐Jacques Kiladjian(Délégation Paris 5), Rami S. Komrokji(Moffitt Cancer Center), Andreas Reiter(Heidelberg University), Faye Feller(Geron (United States)), Dietger Niederwieser(Leipzig University of Applied Sciences), Maria R. Baer(University of Maryland, Baltimore), Jacqueline Bussolari(Johnson & Johnson (United States)), Olatoyosi Odenike(University of Chicago), Fei Huang(Children's Hospital of Zhejiang University), Laurie Sherman(Geron (United States)), Michèle Cavo(Unknown), Bart L. Scott(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Souria Dougherty(Geron (United States)), Eugene Zhu(Janssen (United States)), Esther Rose(The University of Texas MD Anderson Cancer Center), Bruno Martino(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Ronald Hoffman(Icahn School of Medicine at Mount Sinai)
Cited by 34
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k